GANX Biotechnology Penny Stock Uptrending LONG
GANX had been in a tight consolidation channel prior to April 12th. This is the
uncommon high tight flag pattern. Once breaking out, the typical guidance is
the next leg up will be at least the distance of the flagpole portion of the pattern.
On April 12th, a new chief financial officer was appointed to Gain Therapeutics.
( see the link below )
This is part of the push to generate earnings while still developing a pipeline
and potentially the first profitable FDA-approved product. Another view is the
company is trying to clean up its balance sheet and make itself into a takeover
target. One way or another I will not argue with a potential path to shift the
fundamentals nor with the high tight flag pattern breakout. The last session of
the week had a massive wide- ranging engulfing green candle. I will look for more
of the same. The final target is $6.15 as the top of the wick of that candle
while the first target is $5.80 being the top of the upper VWAP band.
uncommon high tight flag pattern. Once breaking out, the typical guidance is
the next leg up will be at least the distance of the flagpole portion of the pattern.
On April 12th, a new chief financial officer was appointed to Gain Therapeutics.
( see the link below )
This is part of the push to generate earnings while still developing a pipeline
and potentially the first profitable FDA-approved product. Another view is the
company is trying to clean up its balance sheet and make itself into a takeover
target. One way or another I will not argue with a potential path to shift the
fundamentals nor with the high tight flag pattern breakout. The last session of
the week had a massive wide- ranging engulfing green candle. I will look for more
of the same. The final target is $6.15 as the top of the wick of that candle
while the first target is $5.80 being the top of the upper VWAP band.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.